Related Experiment Video

Updated: Mar 9, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Insights into the interaction of high potency inhibitor IRC-083864 with phosphatase CDC25

Manal Sarkis1, Maria A Miteva2, Maria Chiara Dasso Lang1

  • 1Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, CNRS UMR8601, Université Paris Descartes, PRES Sorbonne Paris Cité, Faculté des Sciences Fondamentales et Biomédicales, 45 rue des Saints-Pères, Paris, 75006, France.

Proteins
|January 6, 2017
PubMed

Insights

We modeled the binding of IRC-083864, a potent CDC25 inhibitor, to CDC25B using molecular modeling and NMR. This reveals key interactions within the catalytic site, crucial for cancer therapy development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Structural Biology

Background:

  • CDC25 phosphatases are vital for cell cycle regulation.
  • Over-expression of CDC25 phosphatases is linked to human tumors, making them therapeutic targets.

Purpose of the Study:

  • To develop the first binding model of the potent CDC25 inhibitor IRC-083864 to CDC25B.
  • To elucidate key interactions between IRC-083864 and the CDC25B catalytic site.

Main Methods:

  • Combined molecular modeling and Nuclear Magnetic Resonance (NMR) studies.
  • Utilized NMR saturation transfer difference and WaterLOGSY techniques.
  • Investigated interactions using analogues of IRC-083864's quinone units.

Main Results:

  • A molecular model showing IRC-083864 binding to both the active site and inhibitor pocket of CDC25B.
  • NMR data confirmed inhibitor binding zones and supported the docking model.
  • Demonstrated that IRC-083864 competes with CDC25B monomers.

Conclusions:

  • The study provides novel insights into the binding mechanism of IRC-083864 with CDC25B.
  • The developed model is valuable for designing new cancer therapeutics targeting CDC25 phosphatases.
Keywords:
STD-NMRWaterLOGSYcancerdockingprotein-ligand binding

More Related Videos

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF311:44

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3

Published on: January 24, 2016

12.6K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
10.4K